Jane Street
ENVB icon

Jane Street’s Enveric Biosciences ENVB Stock Holding History

Jane Street’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60
Closed -$3.88K – 9694
2024
Q4 		$3.88K Buy
+60
New +$4.35K ﹤0.01% 9224
2019
Q3 		– Hold
0
– -$43K – 5225
2019
Q2 		– Hold
0
– – – 4971
2018
Q3 		– Hold
0
– -$11K – 5229
2018
Q2 		– Hold
0
– – – 4882

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street's ENVB Position: Q1 2025 in Review

Jane Street sold out of Enveric Biosciences (ENVB) in Q1 2025, closing a stake of 60 shares — an estimated $3.88K sold.

Jane Street first reported a position in ENVB in Q4 2024 and held it in 1 quarter. The position peaked at $3.88K in Q4 2024. 13 funds tracked by Wall St. Rank hold ENVB as of Q1 2025.

  • Jane Street reported no remaining Enveric Biosciences position as of Q1 2025 after selling out during the quarter.
  • Jane Street sold 60 Enveric Biosciences shares in Q1 2025, an estimated $3.88K.
  • Jane Street first reported a position in Enveric Biosciences in Q4 2024 and held it in 1 quarter.
  • Jane Street's Enveric Biosciences position peaked at $3.88K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.